Key result
Subcutaneous terbutaline at, but not, increased maternal and fetal heart rates and fetal heart rate accelerations, and decreased uterine basal activity.
Why the study?
Does subcutaneous terbutaline affect maternal and fetal heart rates in term gravidas not in labor?
Does subcutaneous terbutaline affect maternal and fetal heart rates in term gravidas not in labor?
Subcutaneous terbutaline at 500 μg significantly increases maternal and fetal heart rates, demonstrating a direct effect on the fetal heart.
Answers are grounded in this paper and cite their sources.
May warrant fetal heart rate monitoring with 500 μg dosing; leaves open effects in labor and needs randomized confirmation.
The aims of this study were to evaluate the cardiac effects of subcutaneous terbutaline on the mother and fetus. Terbutaline was given in 250 or 500 μg doses to term gravidas not in labor. The mean arterial pressure (MAP), pulse, and uterine activity were measured. The fetal heart rate (FHR), accelerations, and decelerations were recorded. There were significant increases in maternal heart rate, FHR, and FHR accelerations, and a decrease in uterine basal activity after 500 μg, but not significantly after 250 μg of terbutaline. MAP was not significantly increased with either dose, although a small mean increase was observed. Terbutaline has a direct effect on the fetal heart apart from the effect of uterine relaxation.
No takes yet. Share an insight, caveat, or question.
Abdelhak et al. (2011) studied Pregnancy at term. Terbutaline was evaluated on Maternal heart rate, fetal heart rate, and uterine activity. Subcutaneous terbutaline at, but not, increased maternal and fetal heart rates and fetal heart rate accelerations, and decreased uterine basal activity.
Synapse has enriched 10 related papers. Consider them for comparative context: